{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=22",
    "query": {
      "intervention": "Dose Level -1",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 29129,
    "total_pages": 2913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:23:42.441Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01982448",
      "title": "Cisplatin vs Paclitaxel for Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 147,
      "start_date": "2014-04",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01982448"
    },
    {
      "nct_id": "NCT00594555",
      "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia, Blast Crisis",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "CLAG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-11",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-10-31",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594555"
    },
    {
      "nct_id": "NCT02905578",
      "title": "A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Neoplasms, Pancreatic",
        "Pancreas Cancer",
        "Pancreas Neoplasms",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological ascorbate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-11-28",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02905578"
    },
    {
      "nct_id": "NCT02050815",
      "title": "MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "MEK162",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2014-03",
      "completion_date": "2016-08-26",
      "has_results": false,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 5,
      "location_summary": "Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02050815"
    },
    {
      "nct_id": "NCT02839915",
      "title": "Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Folinic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Southwest Autism Research & Resource Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-08-13",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Lexington, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02839915"
    },
    {
      "nct_id": "NCT00527865",
      "title": "Single Dose Escalating Study of DAS181 in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "DAS181",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2007-10",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-01-08",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527865"
    },
    {
      "nct_id": "NCT00418600",
      "title": "A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Hectorol® (doxercalciferol capsules)",
          "type": "DRUG"
        },
        {
          "name": "doxercalciferol capsules, Hectorol®",
          "type": "DRUG"
        },
        {
          "name": "doxercalciferol capsules, Hectorol® capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-19",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 8,
      "location_summary": "Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00418600"
    },
    {
      "nct_id": "NCT01889992",
      "title": "Cardiac Allograft Remodeling and Effects of Sirolimus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiac Hypertrophy",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "Cardiac MRI",
          "type": "RADIATION"
        },
        {
          "name": "Coronary angiography with IVUS",
          "type": "PROCEDURE"
        },
        {
          "name": "Cardiac Allograft Remodeling",
          "type": "OTHER"
        },
        {
          "name": "M-TOR Immunosuppression",
          "type": "DRUG"
        },
        {
          "name": "Cardiac Biopsy C4D stain",
          "type": "PROCEDURE"
        },
        {
          "name": "Genetic Mechanism of M-TOR",
          "type": "GENETIC"
        },
        {
          "name": "Cardiopulmonary Exercise Test (CPET)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "OTHER",
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-04-24",
      "completion_date": "2018-09-27",
      "has_results": false,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01889992"
    },
    {
      "nct_id": "NCT03326336",
      "title": "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-syndromic Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Gene therapy: GS030-DP AND Medical device: GS030-MD",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-26",
      "completion_date": "2027-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326336"
    },
    {
      "nct_id": "NCT00052611",
      "title": "Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2002-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-11-19T01:23:42.441Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052611"
    }
  ]
}